Figure 2.
Gene set enrichment analyses (GSEA) from patients with AML after voruciclib treatment. RNA-seq was performed on PBMCs from 6 patients with AML treated with 100 to 200 mg voruciclib. Normalized gene counts were compiled from bulk RNA-seq analysis and processed using GSEA to identify NES for the top 10 Hallmark pathways by P value (A). (B) GSEA enrichment plots of significantly downregulated oncogenic pathways. (C) Heat map depicting the ranked list of genes with core enrichment for the Hallmark MYC targets V1 pathway. The range of expression values are visualized as red (high) to blue (low). Green bar indicates enriched genes. All data sets shown are represented as on-treatment vs cycle 1 day 1 (C1D1) pretreatment and statistical significance is represented as P < .05. NES, normalized enrichment scores.

Gene set enrichment analyses (GSEA) from patients with AML after voruciclib treatment. RNA-seq was performed on PBMCs from 6 patients with AML treated with 100 to 200 mg voruciclib. Normalized gene counts were compiled from bulk RNA-seq analysis and processed using GSEA to identify NES for the top 10 Hallmark pathways by P value (A). (B) GSEA enrichment plots of significantly downregulated oncogenic pathways. (C) Heat map depicting the ranked list of genes with core enrichment for the Hallmark MYC targets V1 pathway. The range of expression values are visualized as red (high) to blue (low). Green bar indicates enriched genes. All data sets shown are represented as on-treatment vs cycle 1 day 1 (C1D1) pretreatment and statistical significance is represented as P < .05. NES, normalized enrichment scores.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal